Tributary Capital Management LLC Has $18.20 Million Position in Enovis Co. (NYSE:ENOV)

Tributary Capital Management LLC boosted its position in Enovis Co. (NYSE:ENOV - Free Report) by 3.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 422,831 shares of the company's stock after buying an additional 13,641 shares during the quarter. Tributary Capital Management LLC owned approximately 0.77% of Enovis worth $18,203,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. American Century Companies Inc. grew its holdings in shares of Enovis by 78.6% during the second quarter. American Century Companies Inc. now owns 1,511,871 shares of the company's stock valued at $68,337,000 after purchasing an additional 665,208 shares during the last quarter. Magnetar Financial LLC grew its holdings in shares of Enovis by 66.7% during the second quarter. Magnetar Financial LLC now owns 1,104,803 shares of the company's stock valued at $49,937,000 after purchasing an additional 442,051 shares during the last quarter. Diamond Hill Capital Management Inc. grew its holdings in shares of Enovis by 14.5% during the second quarter. Diamond Hill Capital Management Inc. now owns 2,786,034 shares of the company's stock valued at $125,929,000 after purchasing an additional 352,116 shares during the last quarter. Boston Partners grew its holdings in shares of Enovis by 206.5% during the first quarter. Boston Partners now owns 295,969 shares of the company's stock valued at $18,455,000 after purchasing an additional 199,411 shares during the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of Enovis by 100.6% during the first quarter. Janus Henderson Group PLC now owns 378,020 shares of the company's stock valued at $23,606,000 after purchasing an additional 189,584 shares during the last quarter. 98.45% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Needham & Company LLC reduced their price objective on Enovis from $82.00 to $65.00 and set a "buy" rating for the company in a research report on Thursday, August 8th. Evercore ISI reduced their price objective on Enovis from $62.00 to $58.00 and set an "outperform" rating for the company in a research report on Tuesday, October 1st. JMP Securities assumed coverage on Enovis in a research report on Thursday, October 3rd. They set an "outperform" rating and a $62.00 price objective for the company. Finally, JPMorgan Chase & Co. reduced their price objective on Enovis from $53.00 to $50.00 and set a "neutral" rating for the company in a research report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Enovis presently has a consensus rating of "Moderate Buy" and a consensus price target of $67.00.

Enovis Price Performance

ENOV traded up $1.18 during trading on Monday, reaching $41.17. The stock had a trading volume of 709,567 shares, compared to its average volume of 566,671. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of -27.45 and a beta of 1.91. The company has a quick ratio of 1.08, a current ratio of 2.26 and a debt-to-equity ratio of 0.40. Enovis Co. has a 1-year low of $38.27 and a 1-year high of $65.03. The stock has a 50 day moving average of $42.58 and a two-hundred day moving average of $46.36.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported $0.62 earnings per share for the quarter, topping analysts' consensus estimates of $0.59 by $0.03. Enovis had a positive return on equity of 4.06% and a negative net margin of 4.73%. The firm had revenue of $525.20 million during the quarter, compared to the consensus estimate of $525.99 million. During the same period in the prior year, the firm posted $0.61 earnings per share. The firm's revenue for the quarter was up 22.6% compared to the same quarter last year. As a group, equities analysts anticipate that Enovis Co. will post 2.7 EPS for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.